Takeda Pharmaceutical (TKPH) is taking on the world. It's launching four new overseas subsidiaries to market its products, aiming to expand its territory substantially. The four units will be based in Mexico, Sweden, Belgium and Turkey, taking on those countries plus Norway, Denmark and Luxembourg.
The Japanese drugmaker is eyeing Turkey and Mexico because they're growing faster than other, more established markets. The Nordic countries and Belgium/Luxembourg units are on tap because Takeda repurchased Actos rights for those countries, so it will need sales units to deal with the diabetes med there.
First on the new sales units' list will be selling Actos, as well as other, as-yet-unspecified "core products," the company said in a statement. The units will also be working to get new drug approvals in those markets to further expand their local activities. The four new units join sales ops launched in Spain, Portugal, Ireland and Canada earlier this year.
The eventual aim? Going worldwide. According to Alan MacKenzie, EVP for international operations, "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them." Enough said.
- get the Takeda release
- read the Kyodo News story